New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 17, 2014
12:23 EDTACOR, TSLA, EW, COV, SCTY, ORCL, MDT, NFLX, MCRSOn The Fly: Midday Wrap
Stocks on Wall Street were slightly higher at midday after spending the morning fluctuating between narrow losses and marginal gains. The averages are drifting back and forth across the flat line as investors await the conclusion of the Fed's latest rate setting meeting, which kicked off today. ECONOMIC EVENTS: In the U.S., the consumer price index rose 0.4% in May, which was above the consensus forecast for an increase of 0.2%. Housing starts in the month declined 6.5% to a rate of about 1M and building permits slid 6.4% to a rate of 991K, which were both lower than expected. The Federal Reserve began its FOMC meeting, which will conclude tomorrow. COMPANY NEWS: Shares of register system and hospitality software maker Micros Systems (MCRS) surged 18% higher following a report from Bloomberg that the company is in talks to be acquired by tech giant Oracle (ORCL) for "more than" $5B... Shares of Edwards Lifesciences (EW) advanced nearly 5% after the company announced last night that it has received FDA approval for its SAPIEN XT transcatheter aortic heart valve for the treatment of certain high-risk and inoperable cardiovascular patients. Wells Fargo thinks the broad label and range of sizes approved by the FDA are a positive development for the company, while analysts at Canaccord noted that they view Edwards as an attractive acquisition candidate. Yesterday, CRT Capital said that it believes Medtronic's (MDT) acquisition of Covidien (COV) may signal an increase in sector M&A. MAJOR MOVERS: Among the notable gainers was SolarCity (SCTY), which jumped more than 15% after the solar energy system installer agreed to acquire solar panel technology and manufacturing company Silevo for up to $350M dollars. Also rising were shares of another company where Elon Musk is Chairman of the Board, Tesla Motors (TSLA), which rose over 3.5% after New Jersey's assembly approved a bill allowing the company to sell its cars directly in the state and New York Governor Andrew Cuomo signed a direct sales law in the neighboring state. Also higher was Netflix (NFLX), which rose 3% after Morgan Stanley upgraded the stock and research firm Pacific Crest issued a positive take on the shares in separate notes to investors earlier today. Among the noteworthy losers was executive recruiter Korn/Ferry (KFY), which dropped 3.5% after reporting on results during its just completed quarter and giving guidance for its current quarter. Also lower was Acorda Therapeutics (ACOR), which fell 5.5% after announcing an offering of $300M of convertible senior notes. INDEXES: Near midday, the Dow was up 9.46, or 0.06%, to 16,790.47, the Nasdaq was up 17.36, or 0.4%, to 4,338.46, and the S&P 500 was up 2.28, or 0.12%, to 1,940.06.
News For MCRS;ORCL;EW;NFLX;SCTY;TSLA;MDT;COV;ACOR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>
March 16, 2015
10:41 EDTTSLATesla certified pre-owned program launches, Clean Technica says
Subscribe for More Information
10:28 EDTNFLXOptions with increasing implied volatility
Options with increasing implied volatility: PVA NFLX BMRN DNOW MYL TEVA PEP GE
10:07 EDTEWHigh option volume stocks
Subscribe for More Information
10:02 EDTNFLXOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:37 EDTTSLA, NFLXActive equity options trading on open
Subscribe for More Information
09:22 EDTTSLAOn The Fly: Pre-market Movers
Subscribe for More Information
09:01 EDTACORFlex Pharma names Thomas Wessel as Chief Medical Officer
Flex Pharma (FLKS) announced the appointment of Thomas Wessel, M.D., Ph.D., as its Chief Medical Officer, reporting to Christoph Westphal M.D., Ph.D., Flex Pharma’s President, CEO and Chair. Flex Pharma also announced that Elizabeth Woo, M.B.A., has been promoted to Senior VP, Investor Relations and Corporate Communications. Previously, Dr. Wessel has been the Chief Medical Officer of Acorda Therapeutics (ACOR).
07:52 EDTNFLXNetflix downgraded at Evercore ISI
As previously reported, Evercore ISI downgraded Netflix to Sell from Hold. The firm downgraded shares and reduced its price target to $380 from $450 due to increasing competition among existing and emerging distributors combined with content providers who are becoming increasingly leveraged to new channels through OTT offerings of their own. Evercore ISI believes intensifying competition will necessitate increased investment with uncertain returns and lowered estimates.
07:32 EDTORCLUBM Tech to hold a conference
Enterprise Connect 2015 is being held in Orlando, Florida on March 16-19.
07:30 EDTMDT, EWAmerican College of Cardiology to hold an expo
Subscribe for More Information
07:22 EDTEW, MDTMedtronic Edwards Lifesciences data 'impressive,' says Bernstein
Subscribe for More Information
06:16 EDTNFLXNetflix downgraded to Sell from Hold at Evercore ISI
06:05 EDTTSLATesla volatility low into press conference on update 'to end range anxiety'
Tesla Motors March call option implied volatility is at 39, April is at 37, June is at 40; compared to its 26-week average of 45 according to Track Data, suggesting decreasing price movement into a press conference on Thursday on update 'to end range anxiety,' Musk says.
March 15, 2015
17:40 EDTTSLAChina's BYD steps up battery factory race with Tesla, Reuters says
Subscribe for More Information
15:43 EDTTSLATesla press conference on Thursday on update 'to end range anxiety,' Musk says
Tesla CEO Elon Musk tweeted, "Tesla press conf at 9am on Thurs. About to end range anxiety ... via OTA software update. Affects entire Model S fleet." Reference Link
15:27 EDTMDTMedtronic unveils data from high risk study of the CoreValve U.S. pivotal trial
Subscribe for More Information
15:23 EDTMDTMedtronic unveils preclinical outcomes of its novel Drug-Filled Stent
Subscribe for More Information
15:20 EDTMDTMedtronic announces outcomes for its next-generation CoreValve Evolut R System
Medtronic announced initial clinical outcomes for its next-generation CoreValve Evolut R System. At 30-days, the new recapturable, self-expanding valve showed no incidents of all-cause mortality or stroke in a high and extreme risk patient population. Data from the Evolut R Study, which enrolled 60 patients from six centers in the United Kingdom, Australia and New Zealand, were unveiled today at the 64th Annual Scientific Session of the American College of Cardiology. The CoreValve Evolut R System is not approved for commercial use in the United States where it is currently undergoing clinical trials. "Initial clinical experience with the Evolut R system is remarkable and ushers in a new era of TAVR technology that provides increased confidence with recapturability, excellent procedural results, and impressive clinical outcomes," said Ian Meredith, M.D., of Monash Heart - Monash Health, Melbourne, Australia, who is one of the investigators of the study. "The 14 French equivalent delivery system allowed transfemoral access for most patients and the recapturable technology enabled implanters to optimize valve placement for improved annular sealing and reduced conduction disturbances without compromise on mortality or stroke."
14:10 EDTEWEdwards Lifesciences announces data on Sapien 3 transcatheter aortic valve
Edwards Lifesciences announced that 30-day outcomes for high- and intermediate-risk patients treated with the Sapien 3 transcatheter aortic valve demonstrated the lowest all-cause mortality rates of any of the PARTNER studies, as well as excellent clinical outcomes on the other components of the primary endpoint measures of stroke and paravalvular regurgitation. This first report of Sapien 3 data in the United States, and first report on intermediate risk transcatheter aortic valve replacement, TAVR, patients, was presented as part of the late-breaking clinical trials at the American College of Cardiology's 64th Annual Scientific Session in San Diego.
14:04 EDTEWEdwards Lifesciences announces clinical data for high-risk Sapien patients
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use